Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus

Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013–2016 West African outbreak. Mouse models of infection are important tools for the development of therapeutics and vaccines. Exposure of immunocompetent mice to clinical isolates of EBOV is nonlethal; consequently, EBOV requires prior adaptation in mice to cause lethal disease. Until now, the only immunocompetent EBOV mouse model was based on the Mayinga variant, which was isolated in 1976. Here, we generated a novel mouse-adapted (MA)-EBOV based on the 2014 Makona isolate by inserting EBOV/Mayinga-MA mutations into the EBOV/Makona genome, followed by serial passaging of the rescued virus in suckling mice. The resulting EBOV/Makona-MA causes lethal disease in adult immunocompetent mice within 6 to 9 days and has a lethal dose (LD50) of 0.004 plaque forming units (PFU). Two additional mutations emerged after mouse-adaptation in the viral nucleoprotein (NP) and membrane-associated protein VP24. Using reverse genetics, we found the VP24 mutation to be critical for EBOV/Makona-MA virulence. EBOV/Makona-MA infected mice that presented with viremia, high viral burden in organs, increased release of pro-inflammatory cytokines/chemokines, and lymphopenia. Our mouse model will help advance pre-clinical development of countermeasures against contemporary EBOV variants.

[1]  O. Dyer Two Ebola treatments halve deaths in trial in DRC outbreak , 2019, BMJ.

[2]  A. Maxmen Two Ebola drugs show promise amid ongoing outbreak. , 2019, Nature.

[3]  D. Watson-Jones,et al.  Prevention of Ebola virus disease through vaccination: where we are in 2018 , 2018, The Lancet.

[4]  M. Aman,et al.  Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs. , 2018, The Journal of infectious diseases.

[5]  X. Qiu,et al.  The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. , 2018, The Journal of infectious diseases.

[6]  T. Nyenswah,et al.  Recently Identified Mutations in the Ebola Virus-Makona Genome Do Not Alter Pathogenicity in Animal Models. , 2018, Cell reports.

[7]  X. Qiu,et al.  Development and characterization of a guinea pig model for Marburg virus , 2018, Zoological research.

[8]  P. Formenty,et al.  Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report , 2017, The New England journal of medicine.

[9]  Marisa C St Claire,et al.  Animal Models of Ebolavirus Infection. , 2017, Comparative medicine.

[10]  N. Loman,et al.  Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Michael A Proschan,et al.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. , 2016, The New England journal of medicine.

[12]  Ian Goodfellow,et al.  Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  H. Ebihara,et al.  Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis. , 2016, Journal of molecular biology.

[14]  M. Ramakrishnan Determination of 50% endpoint titer using a simple formula. , 2016, World journal of virology.

[15]  Jeffrey R. Kugelman,et al.  Molecular Evidence of Sexual Transmission of Ebola Virus. , 2015, The New England journal of medicine.

[16]  X. Qiu,et al.  Development and Characterization of a Guinea Pig-Adapted Sudan Virus , 2015, Journal of Virology.

[17]  Justine R. Smith,et al.  Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.

[18]  Samantha E. Zak,et al.  Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease. , 2015, The Journal of infectious diseases.

[19]  C. Basler Innate immune evasion by filoviruses. , 2015, Virology.

[20]  Jeffrey M. Weiss,et al.  Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance , 2014, Science.

[21]  D. Huson,et al.  Fast and sensitive protein alignment using DIAMOND , 2014, Nature Methods.

[22]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[23]  Michael McCarthy,et al.  US signs contract with ZMapp maker to accelerate development of the Ebola drug , 2014, BMJ : British Medical Journal.

[24]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[25]  X. Qiu,et al.  Establishment and Characterization of a Lethal Mouse Model for the Angola Strain of Marburg Virus , 2014, Journal of Virology.

[26]  L. Glenn Ebola in the Democratic Republic of the Congo , 2012 .

[27]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[28]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[29]  L. Hensley,et al.  Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. , 2011, The Journal of infectious diseases.

[30]  Steven B. Bradfute,et al.  Filovirus infection of STAT-1 knockout mice. , 2011, The Journal of infectious diseases.

[31]  Steven B. Bradfute,et al.  Development and Characterization of a Mouse Model for Marburg Hemorrhagic Fever , 2009, Journal of Virology.

[32]  Steven B. Bradfute,et al.  Lymphocyte death in a mouse model of Ebola virus infection. , 2007, The Journal of infectious diseases.

[33]  C. Basler,et al.  Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin α Proteins with Activated STAT1 , 2007, Journal of Virology.

[34]  G. Neumann,et al.  Molecular Determinants of Ebola Virus Virulence in Mice , 2006, PLoS pathogens.

[35]  V. Volchkov,et al.  Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation , 2006, Journal of Virology.

[36]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[37]  P. Jahrling,et al.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. , 2003, The American journal of pathology.

[38]  G. Nabel,et al.  The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. , 2002, Molecular cell.

[39]  M. Bray,et al.  Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. , 2001, Journal of comparative pathology.

[40]  M. Bray,et al.  Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. , 2001, Journal of comparative pathology.

[41]  M. Bray The role of the Type I interferon response in the resistance of mice to filovirus infection. , 2001, The Journal of general virology.

[42]  H. Feldmann,et al.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages , 1996, Journal of virology.

[43]  P. Jahrling,et al.  Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. , 1992, Journal of comparative pathology.

[44]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[45]  Jeffrey E. Barrick,et al.  Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. , 2014, Methods in molecular biology.

[46]  V. Volchkov,et al.  Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. , 2006, Journal of virology.

[47]  M. Bray,et al.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. , 1998, The Journal of infectious diseases.